Patents by Inventor David A. Sallman

David A. Sallman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CLINICAL REGIMEN FOR TREATING MYELODYSPLASTIC SYNDROME WITH PHOSPHATASE INHIBITOR
    Publication number: 20220323433
    Abstract: This invention provides a method of treating myelodysplastic syndrome in a human subject afflicted therewith comprising administering to the subject an amount from 0.1 mg/m2 to 5 mg/m2 of a compound having the structure or a salt, zwitterion, or ester thereof.
    Type: Application
    Filed: March 4, 2022
    Publication date: October 13, 2022
    Applicants: H. Lee Moffitt Cancer Center and Research Institute, Inc., Lixte Biotechnology, Inc.
    Inventors: Alan F. LIST, David A. SALLMAN, John S. KOVACH
  • CLINICAL REGIMEN FOR TREATING MYELODYSPLASTIC SYNDROME WITH PHOSPHATASE INHIBITOR
    Publication number: 20220184066
    Abstract: This invention provides a method of treating myelodysplastic syndrome in a human subject afflicted therewith comprising administering to the subject an amount from 0.1 mg/m2 to 5 mg/m2 of a compound having the structure or a salt, zwitterion, or ester thereof.
    Type: Application
    Filed: March 4, 2022
    Publication date: June 16, 2022
    Inventors: ALAN F. LIST, David A. Sallman, John S. Kovach
  • Protein phosphatase 2A inhibitors for treating myelodysplastic syndromes
    Patent number: 10434100
    Abstract: Disclosed are methods for treating a meylodysplastic syndrome (MDS) in a subject that involves administering to the subject a therapeutically effective amount of a protein phosphatase 2A (PP2A) inhibitor.
    Type: Grant
    Filed: August 20, 2018
    Date of Patent: October 8, 2019
    Assignee: Lixte Biotechnology, Inc.
    Inventors: Alan F. List, David A. Sallman, John S. Kovach
  • CLINICAL REGIMEN FOR TREATING MYELODYSPLASTIC SYNDROME WITH PHOSPHATASE INHIBITOR
    Publication number: 20190111053
    Abstract: This invention provides a method of treating myelodysplastic syndrome in a human subject afflicted therewith comprising administering to the subject an amount from 0.1 mg/m2 to 5 mg/m2 of a compound having the structure (I) or a salt, zwitterion, or ester thereof.
    Type: Application
    Filed: January 27, 2017
    Publication date: April 18, 2019
    Inventors: Alan F. List, David A. Sallman, John S. Kovach
  • PROTEIN PHOSPHATASE 2A INHIBITORS FOR TREATING MYELODYSPLASTIC SYNDROMES
    Publication number: 20190046525
    Abstract: Disclosed are methods for treating a meylodysplastic syndrome (MDS) in a subject that involves administering to the subject a therapeutically effective amount of a protein phosphatase 2A (PP2A) inhibitor.
    Type: Application
    Filed: August 20, 2018
    Publication date: February 14, 2019
    Applicants: H. Lee Moffitt Cancer Center and Research Institute, Inc., Lixte Biotechnology, Inc.
    Inventors: Alan F. List, David A. Sallman, John S. Kovach
  • Protein phosphatase 2A inhibitors for treating myelodysplastic syndromes
    Patent number: 10071094
    Abstract: Disclosed are methods for treating a myelodysplastic syndrome (MDS) in a subject that involves administering to the subject a therapeutically effective amount of a protein phosphatase 2A (PP2A) inhibitor.
    Type: Grant
    Filed: July 23, 2015
    Date of Patent: September 11, 2018
    Inventors: Alan F. List, David A. Sallman, John S. Kovach
  • PROTEIN PHOSPHATASE 2A INHIBITORS FOR TREATING MYELODYSPLASTIC SYNDROMES
    Publication number: 20170340628
    Abstract: Disclosed are methods for treating a myelodysplastic syndrome (MDS) in a subject that involves administering to the subject a therapeutically effective amount of a protein phosphatase 2A (PP2A) inhibitor.
    Type: Application
    Filed: July 23, 2015
    Publication date: November 30, 2017
    Applicants: H. Lee Moffitt Cancer Center and Research Institute, Inc., Lixte Biotechnology, Inc.
    Inventors: Alan F. List, David A. Sallman, John S. Kovach
  • PROTEIN PHOSPHATASE 2A INHIBITORS FOR TREATING MYELODYSPLASTIC SYNDROMES
    Publication number: 20170209434
    Abstract: Disclosed are methods for treating a meylodysplastic syndrome (MDS) in a subject that involves administering to the subject a therapeutically effective amount of a protein phosphatase 2A (PP2A) inhibitor.
    Type: Application
    Filed: July 23, 2015
    Publication date: July 27, 2017
    Inventors: Alan F. List, David A. Sallman